Leprosy

2. Leprosy, also known as Hansen’s
disease, is a chronic infectious
disease caused by Mycobacterium
leprae. The disease mainly affects
the skin, the peripheral nerves,
mucosal surfaces of the upper
respiratory tract and the eyes.
Leprosy is known to occur at all
ages ranging from early infancy to
very old age.

3. Disabling
disease
Individual
communities
Mycobaterium
leprae
Mycobacterium
lepromatosis
Ancient disease

4. Gerhard
hansen
Hansen’s
disease(1873)
2018
200,500
cases

6. Infectiou
s
droplets
Prolonged
close
contact
armadillo
s

8. Long incubation period 5 years 1-20 years or more
Skin
Nerves
Discoloure
d patches,
No
sensation
Thickene
d
Reduced
sweating
Not work
weakness
Sensory
loss

9. Sensory loss
Injuri
es

10. Fee
t
Normal
feet
Wounds and
ulcers
Deformity
disfigurem
ent

12. Stigma and
discrimination
Impacts functioning in
society, diagnosis, treatment
and care

14. CLINICAL LABORATORY
Loss of
sensation
Tickened
nerves
Skin patches
mild
Slit skin smears
seve
re

15. WHO
classificatio
n
Ridlery
jopling
pacucibacil
lary
mutibacill
ary
Tubercul
iod
TT
Boderli
ne
tubercu
liod
BT
Boderli
ne BB
Boderline
Lepromato
us
BTLepromat
ous
BT
DEPENDS ON HOW
WELL THE IMMUNE
SYSTEM REPONDS

17. MEDICATIO
N
MANAGING
COMPLICATION
S
COMBINATION OF
DRUGS
SEVERAL
MONTHS
DEPENDS ON TYPES
OF LEPROSY
REACTIVE
EPISODES
IMMUNE RESPONS TO
DISEASE•READNESS AND
SWEELING OF SKIN
PATCHES
•PAIN AND
TENDERENESS OF
NERVES
TYPE 1
• FEVER , MALAISE
• ERYTHEMA
NODOSOM
TYPE 2
MEDICATION

18. PREVENTING
DISABLITY
LOOK AFTER
WEAK OR
NUMB
AREASINSPECTION
AND
CLEANING
FOOT WARE
RECONSTRU
CTIVE
SURGERY

20. NOT VERY
INFECTIOUS
DOES NOT SPREAD
THAT EASILY
NO VACCINE (BCG
VACCINE)

21. WORLD
HEALTH
ORGANISAT
ION
PHARMACE
UTICAL
COMPANIES
NATIONAL
LEPROSY
PROGRAM
NGO’s

22. WHO Global leprosy
strategy
Strengthen government
ownership coordination and
parternship
Stop leprosy and
complications